# Congenital Hypothyroidism

Manage an abnormal newborn screen as a time-critical thyroid hormone deficiency: confirm with serum testing, begin levothyroxine promptly, monitor free T4 and TSH intensively, and use thyroid imaging to clarify permanence without delaying treatment.

**Clinical question:** How should physicians confirm, treat, monitor, and determine the likely cause of congenital hypothyroidism after an abnormal newborn screen?

Updated: 2026-08-21T02:41:17.907728+00:00

## What matters in practice
- Initiate levothyroxine immediately once congenital hypothyroidism is diagnosed; rapid restoration of serum T4 is necessary to protect intellectual development, growth, and maturation. [2][3]
- For neonatal primary congenital hypothyroidism, use levothyroxine 10-15 mcg/kg/day; lower initial doses are indicated for newborns at risk for cardiac failure. [3]
- Measure both TSH and total or free T4 at 2 and 4 weeks after treatment starts, 2 weeks after every dose change, then every 3-12 months after stabilization through completion of growth. [8]
- Do not use TSH to titrate central hypothyroidism; titrate levothyroxine to clinical euthyroidism and free T4 in the upper half of the reference range. [5][8]
- Thyroid dysgenesis, including aplasia and ectopic thyroid, accounts for approximately 85% of congenital hypothyroidism; imaging can help predict permanence but must not postpone treatment. [12][19]

## Treat confirmed congenital hypothyroidism without delay

The immediate priority is restoration of circulating thyroid hormone.

After a positive newborn-screen result, obtain confirmatory serum TSH and total or free T4 promptly and initiate levothyroxine immediately when congenital hypothyroidism is diagnosed. Rapid restoration of normal serum T4 is necessary to prevent adverse effects on intellectual development, linear growth, and maturation; levothyroxine treatment is generally lifelong in congenital hypothyroidism. [2][3]

Use oral levothyroxine rather than an oral thyroid hormone product for myxedema coma; the levothyroxine tablet label specifically states that oral thyroid hormone products should not be used for myxedema coma. If adrenal insufficiency is present or suspected, give glucocorticoid replacement before levothyroxine because uncorrected adrenal insufficiency is a contraindication and thyroid hormone can precipitate acute adrenal crisis. [7][9]

During the first 2 weeks of therapy, monitor newborns for cardiac overload, arrhythmias, and aspiration associated with avid suckling. The treatment tradeoff is narrow: undertreatment risks impaired neurodevelopment and growth, whereas overtreatment in infancy is associated with craniosynostosis, accelerated bone age, and potentially adverse brain maturation. [2][3][6][8]
- Do not delay levothyroxine initiation for ultrasound, radionuclide scintigraphy, genetic testing, or determination of transient versus permanent disease. Thyroid imaging and treatment-response patterns are prognostic tools, not prerequisites for replacement. [19]
- Do not prescribe levothyroxine for obesity or weight loss; doses above physiologic requirements can cause serious or life-threatening toxicity. [1][6]

*Initial levothyroxine dosing for pediatric hypothyroidism. [3]*

| Age | Recommended daily levothyroxine dose |
| --- | --- |
| 0-3 months | 10-15 mcg/kg/day; use a lower starting dose when cardiac-failure risk is present. [3] |
| 3-6 months | 8-10 mcg/kg/day. [3] |
| 6-12 months | 6-8 mcg/kg/day. [3] |
| 1-5 years | 5-6 mcg/kg/day. [3] |
| 6-12 years | 4-5 mcg/kg/day. [3] |

## Use TSH and free T4 according to the anatomic level of disease

The monitoring analyte changes when hypothyroidism is central rather than primary.

In primary congenital hypothyroidism, use serial serum TSH with total or free T4 to assess replacement adequacy. A persistently abnormal TSH or thyroid hormone concentration should trigger review of dose, administration, adherence, food exposure, and interacting medications before assuming an unusual biologic requirement. Persistent biochemical hypothyroidism despite an apparently adequate dose may reflect inadequate absorption, nonadherence, drug interactions, or a combination of these factors. [4]

In secondary or tertiary hypothyroidism, TSH is not a reliable index of replacement adequacy. Titrate levothyroxine to clinical euthyroidism and a free T4 concentration in the upper half of the reference range, rather than escalating therapy in response to TSH alone. [5][8]

Interpret TSH cautiously during early treatment of congenital hypothyroidism. Some infants can have a serum TSH above 20 mU/L despite a serum T4 in the upper half of the normal range; free or total T4 therefore remains necessary for early treatment assessment. [10]
- Stop biotin and biotin-containing supplements for at least 2 days before measuring TSH or T4 to reduce assay interference. [4]
- In an infant with congenital hypothyroidism, include serial clinical assessment of development, physical growth, and bone maturation with biochemical monitoring. [8]

*Laboratory-directed monitoring decisions in congenital hypothyroidism. [5][8][10]*

| Clinical setting | Primary monitoring tests | Interpretation and next action |
| --- | --- | --- |
| Primary congenital hypothyroidism | TSH plus total or free T4. [8] | Use both measures to assess replacement; investigate administration, absorption, adherence, and interactions when hypothyroid results persist despite an apparently adequate dose. [4] |
| Secondary or tertiary hypothyroidism | Free T4. [5][8] | Do not titrate to TSH; target clinical euthyroidism and free T4 in the upper half of the reference range. [5][8] |
| Early treatment of congenital hypothyroidism | TSH plus total or free T4. [8][10] | An elevated TSH, including values above 20 mU/L, can coexist with T4 in the upper half of normal in some infants; assess T4 rather than reacting to TSH in isolation. [10] |

## Monitor intensively during infancy and after every dose adjustment

Frequent testing reduces both prolonged undertreatment and iatrogenic hyperthyroxinemia.

For congenital hypothyroidism, check serum TSH and total or free T4 at 2 and 4 weeks after starting levothyroxine, then 2 weeks after each dosage change. After stabilization, repeat testing every 3-12 months until growth is complete; abnormal values or poor adherence warrant more frequent assessment. [8]

Use the full age-based daily dose in most pediatric patients. Start below full replacement in newborns 0-3 months at risk for cardiac failure; similarly, lower initial dosing is appropriate in elderly patients, patients with cardiovascular disease, and patients with severe longstanding hypothyroidism because thyroid hormone can provoke cardiac adverse reactions including atrial fibrillation. [3][7][9]

Account for changing requirements during growth and for factors that alter levothyroxine exposure, including food, concomitant medications, clinical comorbidity, and pregnancy in later life. Levothyroxine has a narrow therapeutic index, so dose changes should follow laboratory reassessment and clinical status rather than empiric escalation. [1][4][6]
- Assess developmental progress, linear growth, physical examination findings, and bone maturation at regular intervals in addition to laboratory measures. [8]
- When TSH or T4 results are discordant, first verify dose administration and assay conditions, including recent biotin exposure, before changing the dose. [4]

*Follow-up schedule for children receiving levothyroxine for congenital hypothyroidism. [8]*

| Time point | Required assessment | Action if abnormal |
| --- | --- | --- |
| 2 weeks after starting treatment | TSH and total or free T4; assess for cardiac overload, arrhythmia, and aspiration during the first 2 treatment weeks. [8] | Adjust clinical surveillance and replacement based on biochemical and clinical response. [8] |
| 4 weeks after starting treatment | TSH and total or free T4. [8] | Titrate levothyroxine to avoid under- or overtreatment. [8] |
| 2 weeks after any dose change | TSH and total or free T4. [8] | Reassess dose adequacy and administration factors. [4][8] |
| After dose stabilization | TSH and total or free T4 every 3-12 months until growth is complete, plus growth, development, and bone maturation assessment. [8] | Increase monitoring frequency for poor adherence or abnormal results. [8] |

## Use thyroid anatomy and treatment trajectory to estimate permanence

Etiologic classification informs prognosis but should not interrupt replacement.

Prioritize thyroid dysgenesis when thyroid imaging shows aplasia, ectopia, or a dysgenetic gland. Thyroid aplasia or ectopic thyroid constitutes approximately 85% of congenital hypothyroidism, and ectopic thyroid development is the most frequent form of thyroid dysgenesis. [11][12]

Consider dyshormonogenesis when congenital hypothyroidism occurs with a gland in situ and investigate a genetic biosynthetic defect when the clinical setting supports it. Congenital hypothyroidism can result from mutations in multiple genes involved in thyroid hormone biosynthesis, including inactivating mutations in thyroid oxidase 2. [13][14]

Use thyroid gland imaging, TSH at diagnosis and during therapy, levothyroxine dose requirement, and need for dose escalation as predictors of transient versus permanent disease; these factors are associated with, but do not definitively establish, disease permanence. Higher diagnostic TSH concentrations are reported in thyroid dysgenesis than in infants with eutopic glands. [19][20]

In very premature or NICU infants with delayed TSH elevation, maintain concern for transient disease while ensuring replacement when indicated. In one cohort, 93% of children with delayed TSH elevation recovered spontaneously or after levothyroxine treatment, although permanent disease was identified during the first 6 months of life. [18]
- Use thyroid ultrasound and, where available, thyroid scintigraphy to define gland size, location, and functional state when etiologic clarification will affect counseling or future reassessment. [19][24]
- Do not infer transient disease from a normal-appearing gland alone; integrate imaging with TSH severity, longitudinal levothyroxine requirement, and dose-escalation history. [19][20]

*Etiologic patterns that change prognosis and follow-up in congenital hypothyroidism. [11][12][13][18][19][20][24]*

| Pattern | Discriminating findings | Clinical implication |
| --- | --- | --- |
| Thyroid dysgenesis | Aplasia, ectopic gland, or dysgenetic gland on imaging; dysgenesis is responsible for about 85% of congenital hypothyroidism. [11][12] | Supports permanent primary hypothyroidism and informs family counseling; continue replacement while monitoring biochemical response. [12][19] |
| Dyshormonogenesis | Thyroid gland in situ with evidence suggesting impaired hormone biosynthesis; multiple biosynthetic genes can be involved. [13][14] | Consider genetic etiology when phenotype and family context support it; continue levothyroxine while defining cause. [13][14] |
| Delayed TSH elevation in preterm or NICU infant | TSH elevation emerging after initial newborn screening; preterm and low-birth-weight infants are overrepresented among false-negative TSH-based screens. [18][21] | Use repeat thyroid testing per neonatal screening protocols and longitudinally reassess permanence; recovery is common but permanent disease can occur early. [18] |
| Possible transient congenital hypothyroidism | Eutopic gland, lower longitudinal levothyroxine requirement, or absence of dose escalation may favor transience, but no single feature is definitive. [19][20] | Plan structured reassessment of ongoing replacement need using endocrine follow-up rather than prematurely discontinuing treatment. [19][20] |

## Recognize infants who can be missed by a single newborn screen

Preterm and low-birth-weight infants require particular attention to delayed biochemical disease.

A single newborn-screen result does not exclude later TSH elevation in preterm or low-birth-weight infants. Immaturity of the hypothalamic-pituitary-thyroid axis makes these infants disproportionately represented among false-negative results in TSH-based screening programs; serial screening is therefore relevant in this population. [18][21]

Screening strategy affects what is detected. Primary TSH screening and primary T4 with reflex TSH identify congenital hypothyroidism through different pathways, and U.S. programs have commonly used an initial dried-blood-spot total T4 followed by TSH testing in infants with low T4 values. [22]

When an infant has delayed TSH elevation, use the same clinical priorities as for other suspected congenital hypothyroidism: obtain serum TSH and free or total T4, determine whether replacement is needed, and maintain longitudinal follow-up to distinguish recovery from permanent disease. [18][8]
- In high-risk premature or NICU infants, verify that repeat newborn screening or repeat serum thyroid testing has occurred according to the applicable state or institutional program. [18][21]
- Do not interpret a normal initial screen as definitive in an infant who subsequently has laboratory or clinical findings concerning for hypothyroidism. [18][21]

*Screening-related situations requiring a different next step. [18][21][22]*

| Situation | Why the initial result may mislead | Next step |
| --- | --- | --- |
| Very preterm or low-birth-weight infant | Hypothalamic-pituitary-thyroid axis immaturity increases the risk of false-negative TSH-based screening. [21] | Confirm completion of serial newborn screening or repeat thyroid testing under the relevant program. [18][21] |
| Delayed TSH elevation | Initial screening may precede the biochemical abnormality. [18] | Obtain serum TSH and total or free T4 and follow longitudinally for transient versus permanent disease. [18][8] |
| Low dried-blood-spot T4 pathway | Programs may use T4 screening with secondary TSH testing rather than primary TSH. [22] | Interpret the result within the state screening algorithm and proceed to confirmatory serum testing when referred. [22] |

## References
1. [PDF] levothyroxine sodium tablet Preferred Pharmaceuticals Inc. - DailyMed — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=4a2c8e57-d52d-409f-83d8-731b721bf613&type=pdf
2. LEVO-T® (levothyroxine sodium) tablets, for oral use — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021342s023lbl.pdf
3. 214047Orig1s000 | FDA - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214047Orig1s000lbl.pdf
4. levothyroxine sodium tablet Mylan Pharmaceuticals Inc. — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=e95720f2-91c9-a6d0-f7d5-8bcb94d07bbc&type=pdf
5. levothyroxine sodium tablet Preferred Pharmaceuticals, Inc. — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=e36f4119-f2b5-4d7a-9180-1cbc5d5da3c2&type=pdf
6. Mylan Pharmaceuticals Inc. LEVOTHYROXINE SODIUM- levothyroxine sodium ... — www.dailymed.nlm.nih.gov — https://www.dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=E95720F2-91C9-A6D0-F7D5-8BCB94D07BBC&name=E95720F2-91C9-A6D0-F7D5-8BCB94D07BBC
7. These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM TABLETS safely and effectively. See full prescribing information for LEVOTHYROXINE SODIUM TABLETS. <br/> <br/> <br/> <br/> <br/> <br/> <br/> <br/> LEVOTHYROXINE SODIUM tablets, for oral use <br/> <br/> <br/> <br/> <br/> <br/> <br/> <br/> Initial U.S. Approval: 2002 — nctr-crs.fda.gov — https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/775ef7ba-0b5b-40ba-ac7b-2aef121fe4f4/spl-doc?hl=
8. <content styleCode="bold">These highlights do not include all the information needed to use <content styleCode="bold">THYQUIDITY <sup>®</sup> </content>safely and effectively. <content styleCode="bold"> See full prescribing information for <content styleCode="bold"> <content styleCode="bold">THYQUIDITY <sup>®</sup> </content> </content>. </content> </content> <br/> <br/> <content styleCode="bold"> <content styleCode="bold"> <content styleCode="bold">THYQUIDITY <sup>®</sup> </content> </content> (levothyroxine sodium) oral solution </content> <br/> <content styleCode="bold">Initial U.S. Approval: 2000</content> — nctr-crs.fda.gov — https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/c17ec992-a122-4cd9-8469-d91255c32440/spl-doc
9. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021402s036lbl.pdf
10. 21-342 Levothyroxine Sodium Medical Review Part 2 — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-342_Levothyroxine%20Sodium_medr_P2.pdf
11. Case 13-2021: A Newborn Girl with a Neck Mass — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJMcpc2100277?listPDF=true
12. Familial Forms of Thyroid Dysgenesis among Infants with ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM200008103430614
13. Thyroid Disorders in Children and Adolescents: A Review — jamanetwork.com — https://jamanetwork.com/HttpHandlers/ArticlePdfHandler.ashx?journal=PEDS&articleId=2546548&pdfFileName=prv160001.pdf
14. Inactivating Mutations in the Gene for Thyroid Oxidase 2 ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa012752
15. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis ... — www.ahajournals.org — https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000001193
16. Thyroid Function and Human Reproductive Health — academic.oup.com — https://academic.oup.com/edrv/article/31/5/702/2354820
17. TSH measurements from blood spots on filter paper: A confirmatory screening test for neonatal hypothyroidism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0022347676803848
18. The natural history of congenital hypothyroidism with delayed TSH elevation in neonatal intensive care newborns - Zung - 2020 - Clinical Endocrinology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/cen.14173
19. Permanent or Transient Congenital Hypothyroidism: A Diagnostic Dilemma - Dermitzaki - Acta Paediatrica - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/apa.70312?af=R
20. Permanent or Transient Congenital Hypothyroidism: A Diagnostic Dilemma - Dermitzaki - 2026 - Acta Paediatrica - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/apa.70312
21. Neonatal screening for congenital hypothyroidism: Time to lower the TSH threshold in France - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0929693X22000665
22. Diagnostic effectiveness of TSH screening and of T4 with secondary TSH screening for newborn congenital hypothyroidism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0009898198000576
23. Targeted Levothyroxine Therapy for Treatment of Congenital Hypothyroidism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1530891X20352435
24. SNMICON 2024 Abstracts : Indian Journal of Nuclear ... — journals.lww.com — https://journals.lww.com/ijnm/fulltext/2024/39001/snmicon_2024_abstracts.1.aspx

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.